The quality of the revised apps is limited. Only one app complied with the excellence criteria, and over 50% of the apps did not exceed minimum quality standards. The worst rated aspects were political advertising and logical security.

Objective The aim of the present work was to identify available mobile healthcare applications related to the pathophysiology and pharmacotherapy of HIV/AIDS and review their characteristics and content, as well as assess the level of involvement of medical professionals in their design. Methods A descriptive observational study was carried out in May 2013. Smartphone apps related to HIV/AIDS were searched for in the Apple App Store (iOS) and the Google Play Store (Android) by keyword. Data recorded included: name, platform, cost, category, number of ratings, user star rating, number of downloads, date the app was updated by the developer, target audience and whether the app was created from a website. We analysed the content of the applications, and these were then categorised into six groups. We conducted an analysis in which we specifically examined the authorship in order to gauge the prevalence of medical professional involvement in their development and content. Results A total of 54 apps were included (from 1908 that were identified), among which there were 13 duplicates. Most of these apps were uploaded under the medical category. Seven had ratings <3.9 stars (out of 5). Only 4 apps had exceeded 1000 downloads, with a mean of 100-500 downloads. A total of 15 apps were aimed at health professionals, while 12 focused on patients. We identified 16 applications created from websites. The involvement of health professionals in the development of apps was 48.8%. Conclusions The current availability of HIV/AIDS applications is limited. Despite the high scores given by users, the number of downloads is low. More than half of the applications do not have the scientific backing of a healthcare professional.

Purpose The ageing population with multiple sclerosis could be related to potentially inappropriate medication prescriptions, drug-drug interactions and therapeutic non-adherence. The PIMDINAC criteria aim to jointly analyse these problems. The aim of the study is to determine the prevalence of PIMDINAC criteria in a multiple sclerosis population aged 55 years or older. Methods Observational, cross-sectional study that included patients over 55 years of age in pharmacotherapy follow-up between November 2022 and January 2023. The main variable was the percentage of compliance with the PIMDINAC criteria. Results 95 patients were included, detecting the presence of PIMDINAC criteria in 67.4%. The most frequently detected was non-adherence to concomitant treatment in 84.4% of cases followed by drug-drug interactions in 56.2% and potentially inappropriate medication in 25%. The number of drugs and polypharmacy were related to a higher occurrence of PIMDINAC criteria. A total of 20 pharmaceutical interventions were performed in 17 patients (17.9%), PIM criteria were responsible for 11 interventions, NAC for 7 and DI for 2. Of the 11 interventions on PIM criteria, 9 (81.8%) were accepted resulting in the discontinuation of 15 drugs that were appropriately prescribed. Conclusion The prevalence of PIMDINAC criteria in elderly MS patients is high.